Home > Compound List > Compound details
267243-28-7 molecular structure
click picture or here to close

N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

ChemBase ID: 72462
Molecular Formular: C24H25ClFN5O3
Molecular Mass: 485.9384032
Monoisotopic Mass: 485.16299559
SMILES and InChIs

SMILES:
c1(c(cc2c(c1)c(ncn2)Nc1cc(c(cc1)F)Cl)OCCCN1CCOCC1)NC(=O)C=C
Canonical SMILES:
C=CC(=O)Nc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F
InChI:
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
InChIKey:
OMZCMEYTWSXEPZ-UHFFFAOYSA-N

Cite this record

CBID:72462 http://www.chembase.cn/molecule-72462.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
IUPAC Traditional name
canertinibumcanertinib
canertinib
Synonyms
Canertinib
PD-183805
PD183805
CI-1033(Canertinib)
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide
N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide
Canertinib
CAS Number
267243-28-7
PubChem SID
162037387
PubChem CID
156414

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID
PubChem 156414 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 12.538747  H Acceptors
H Donor LogD (pH = 5.5) 2.4924963 
LogD (pH = 7.4) 3.7905312  Log P 3.9026284 
Molar Refractivity 130.5543 cm3 Polarizability 49.885162 Å3
Polar Surface Area 88.61 Å2 Rotatable Bonds
Lipinski's Rule of Five true 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
DMSO expand Show data source
Methanol expand Show data source
Apperance
Pale Yellow Solid expand Show data source
Melting Point
175-180°C expand Show data source
Storage Condition
-20°C expand Show data source
-20°C Freezer expand Show data source
MSDS Link
Download expand Show data source
Target
EGFR expand Show data source
HER2 expand Show data source
Salt Data
Free Base expand Show data source
Certificate of Analysis
Download expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals TRC TRC
Selleck Chemicals - S1019 external link
Research Area
Description Cancer
Biological Activity
Description CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.
Targets EGFR ErbB2
IC50 1.5 nM 9.0 nM [1]
In Vitro CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB 453 cells. CI-1033 also shows high permeability in Caco-2 cells and inhibits secretory transport of vinblastine, which indicates that CI-1033 is a likely inhibitor of the P-gp. [1] CI-1033 alone, significantly suppresses constitutively activated Akt and MAP kinase. In combination with gemcitabine, CI-1033 inhibits Akt and prevents increased levels of MAPK phosphorylation. CI-1033 stimulates p27 expression and p38 phosphorylation in MDA-MB-453 cells. [2] CI-1033 is highly specific to the erbB receptor family and not sensitive to PGFR, FGFR or IR even at 50 μM. CI-1033 shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM. CI-1033 suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. CI-1033 also inhibits expression of pp62c-fos in response to heregulin. [3] CI-1033 is predicted to modify Cys773 covalently within the ATP binding site of the HER2 kinase and enhances destruction of both mature and immature ErbB-2 molecules. [4] CI-1033 induces a significant decrease in measurable phosphorylation of tyrosine residues 845 and 1068 of EGFR, which are responsible for Src and Ras/MAPK signaling respectively. The corresponding residues of Her-2, tyrosine residues 877 and 1248 are dephosphorylated significantly by CI-1033 at a concentration of 3 μM or higher. CI could block EGFR internalization and increase the rate of apoptosis in primary osteosarcoma cells in a titratable fashion. [5] In addition, CI-1033 inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM. [6]
In Vivo CI-1033 shows impressive activity against A431 xenografts in nude mice at 5 mg/kg of body weight. [1] CI-1033 (20 to 80 mg/kg/d) achieves a high degree of tumor regressions in H125 xenograft models. [3] Oral administration of CI-1033 causes a marked inhibition of growth in TT, TE6 and TE10 xenografts in nude mice, without animal death and <10% weight="" loss.="">[6]
Clinical Trials Phase II trials have been completed in patients with metastatic breast cancer.
Features CI-1033 is the first kinase inhibitor showing irreversible activity to enter clinical trials and has become a template for further development.
Combination Therapy
Description CI-1033 (6 μM) combined with SN-38 (active metabolite of Irinotecan, 12 nM) show synergistic cytotoxicity in T98G cells. CI-1033 (8 μM) combined with SN-38 (10 nM) enhance the effect of SN-38 to delay T98G cells at G2-M phase. [7]
Protocol
Kinase Assay [1]
Tyrosine Kinase Assays Enzyme assays for determination of IC50 are performed in 96-well filter plates in a total volume of 0.1 mL, containing 20 mM Hepes, pH 7.4, 50 mM sodium vanadate, 40 mM magnesium chloride, 10 μM adenosine triphosphate (ATP) containing 0.5 mCi of [32P]ATP, 20 mg of polyglutamic acid/tyrosine, 10 ng of EGFR tyrosine kinase, and appropriate dilutions of CI-1033. All components except the ATP are added to the well and the plate is incubated with shaking for 10 min at 25 °C. The reaction is started by adding [32P]ATP, and the plate is incubated at 25 °C for another 10 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate is kept at 4 °C for at least 15 min to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL of 10% TCA and 32P incorporation determined with a Wallac β plate counter.
Cell Assay [6]
Cell Lines TT, TE2, TE6 and TE10 cells
Concentrations 0.1-5.0 nM
Incubation Time 1, 3, 5 and 7 days
Methods Cells (1 × 104) are seeded in each well of a 24-well plastic culture plate and left overnight in DMEM or RPMI-1640 supplemented with 10% FBS. The next morning, the cells are treated with the indicated concentrations of CI-1033 (0.1-5.0 nM) for varying periods (1, 3, 5 and 7 days). After treatment, the cells are counted using a Coulter counter. The percent of cell proliferation is calculated by this formula: treatment cell number/control cell number × 100 for each time period.
Animal Study [1]
Animal Models A431 xenografts established in nude mice
Formulation In solution as the isethionate salts
Doses ~18 mg/kg
Administration Administered orally
References
[1] Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397.
[2] Nelson JM et al. J Biol Chem. 2001; 276(18): 14842-14827.
[3] Slichenmyer WJ et al. Semin Oncol. 2001; 28(5 Suppl 16): 80-85.
[4] Citri A et al. EMBO J. 2002; 21(10): 2407-2417.
[5] Hughes DP et al. Pediatr Blood Cancer. 2006; 46(5): 614-623.
[6] Ako E et al. Oncol Rep. 2007; 17(4): 887-893.
[7] Erlichman C, et al. Cancer Res, 2001, 61(2), 739-748.
Toronto Research Chemicals - C175600 external link
Antineoplastic; irreversible pan-erbB tyrosine kinase inhibitor used to treat cancer.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle